Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma

Press/Media

Period	21 Feb 2023

Media coverage

Title	Nivolumab Plus Cabozantinib Benefits Consistent at 3 Years for Renal Cell Carcinoma
Media name/outlet	HMP Global Learning Network
Country/Territory	United States
Date	21/02/23
URL	ct.moreover.com/?a=50070010351&p=1gw&v=1&x=34a8Am2BtPT9wpFxZ8p9Xw
Persons	Mauricio Burotto